Viewing Study NCT01915602

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2025-12-26 @ 2:32 AM
Study NCT ID: NCT01915602
Status: COMPLETED
Last Update Posted: 2021-04-08
First Post: 2013-07-24
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Hepatocellular View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hepatocellular Carcinoma View
None Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor View
None Sorafenib View
None Objective tumor response rate (ORR) View
None modified RECIST criteria View